Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May 12;110(5):3087-111.
doi: 10.1021/cr900361p.

Peptides and peptide hormones for molecular imaging and disease diagnosis

Seulki Lee  1 , Jin Xie, Xiaoyuan Chen
Affiliations
Review

Peptides and peptide hormones for molecular imaging and disease diagnosis

Seulki Lee et al. Chem Rev. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selected macrocyclic chelators.
Figure 2
Figure 2
Selected bifunctional DOTA analogs.
Figure 3
Figure 3
Selected chelating agents for 99mTc.
Figure 4
Figure 4
18F-labeled small molecule tracers.
Figure 5
Figure 5
Radio-labeling of peptide with 18F.
Figure 6
Figure 6
Selected 18F synthons.
Figure 7
Figure 7
Radio-labeling of peptide with 18F via click chemistry.
Figure 8
Figure 8
Selected somatostatin analogs.
Figure 9
Figure 9
(A) Selected RGD analogs for PET imaging. (B) Serial microPET images of U87MG tumor-bearing mice after intravenous injection of [18F]FPRGD2. Arrow indicates tumor. Modified with permission from ref. . Copyright 2007, Springer-Varlag.
Figure 10
Figure 10
(A) Selected RGD-BBN heterodimers. (B) Coronal microPET images of PC-3 tumor-bearing mice at 1 h after intravenous injection of [18F]FB-PEG3-Glu-RGD-BBN and a blocking dose of BBN peptide, c(RGDyK), or RGD + BBN peptides. Arrows indicate tumors. Modified with permission from ref. . Copyright 2009, American Chemical Society.
Figure 11
Figure 11
(A) Structure of [111In-Ahx-DTPA-Lys40]-Exendin-4. (B) GLP-1 receptor scanning of insulinoma; (left) coronal SPECT image of a tumor bearing Rip1Tag2 mouse and (right) transaxial SPECT image of an insulinoma in patient. Arrows indicate tumors. Modified with permission from ref. and . Copyright 2006, the Society of Nuclear Medicine, Inc. Copyright 2008, the Massachusetts Medical Society.
Figure 12
Figure 12
Selected near-infrared (NIR) dyes.
Figure 13
Figure 13
Simple schematic diagram of peptide-based activatable probe; D: Dye and Q: quencher.
Figure 14
Figure 14
(A) Structure of c(RGDyK)-Cy5.5. (B) In vivo NIR fluorescence images of U87MG tumor-bearing mice at 4 h after intravenous injection of c(RGDyK)-Cy5.5 only (left) and a blocking dose of c(RGDyK) peptide (right). Modified with permission from ref. . Copyright 2004, the American Association for Cancer Research.
Figure 15
Figure 15
(A) Structure of MMP-13 activatable peptide-based probe, Cy5.5-GPLGGMRGLGK(BHQ-3)-NH2. (B) NIR fluorescence image of the probe in various concentrations of MMP-13 after a 40 min incubation at 37°C. In vivo imaging of upregulated MMP-13 in normal, six and eight week OA-induced cartilages 1 h after intracartilage-injection of the probe; (left) NIR fluorescence reflectance imaging of normal and OA cartilage after local injection of the probe, (right) histological evaluation of normal, six and eight week OA joints by Safranin-O staining, Arrows; dotted line (normal) and solid line (OA). Modified with permission from ref. . Copyright 2009, American Chemical Society.
Figure 16
Figure 16
Nanoparticle-labeling of peptides.
Figure 17
Figure 17
(A) Schematic diagram of 64Cu-DOTA-IONPs-c(RGDyK) probe for PETG and MRI imaging. (B) microPET image of U87MG tumor-bearing mouse at 4 h after intravenous injection of the probe. T2-weighted MR images of mice (the arrow indicates the tumor) C) before and D) 4 h after intravenous injection of the probe. Modified with permission from ref. . Copyright 2008, the Society of Nuclear Medicine, Inc.
Figure 18
Figure 18
(A) Schematic diagram of QD705-RGD. (B) Staining of live U87MG cells with QD705-RGD (left) and QD705 (right). (C) In vivo NIR fluorescence imaging of U87MG tumor-bearing mice at 6 h after intravenous injection of QD705-RGD (left) or QD705 (right). Arrows indicate tumors. Modified with permission from ref. . Copyright 2009, American Chemical Society.
Figure 19
Figure 19
(A) Schematic diagrams of single-walled carbon nanotubes (plain SWNT) and SWNT–RGD. (B) Photographs of the tumors in mice and the corresponding photoacoustic subtraction images (green) shown as horizontal slices through the tumors. After the photoacoustic scan, the tumors were excised and scanned using a Raman microscope (red). Modified with permission from ref. . Copyright 2008, Macmillan Publishers Limited.
Figure 20
Figure 20
(A) Schematic diagrams of MMPs activatable polymeric nanoparticle-based probe. (B) Structures of the probe. (C) In vivo NIR fluorescence images of subcutaneous MMP-positive SCC7 tumor-bearing mice after intravenous injection of the probe with or without the MMP inhibitor. Only tumors injected with the probe without inhibitor were clearly visualized. (D) Upper: photo image of colon tumors from an A/J mouse treated with azoxymethane (AOM), lower: NIR fluorescence image of MMP-positive colon tumors after intravenous injection of the probe.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hoffman JM, Gambhir SS. Radiology. 2007;244:39. - PubMed
    1. Cai W, Chen X. Small. 2007;3:1840. - PubMed
    1. Wu AM, Olafsen T. Cancer J. 2008;14:191. - PubMed
    1. Zaccaro L, Del Gatto A, Pedone C, Saviano M. Curr. Med. Chem. 2009;16:780. - PubMed
    1. Schottelius M, Wester HJ. Methods. 2009;48:161. - PubMed

Publication types